Edition:
United States

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

0.80USD
15 Dec 2017
Change (% chg)

$-0.01 (-1.23%)
Prev Close
$0.81
Open
$0.85
Day's High
$0.85
Day's Low
$0.77
Volume
26,411
Avg. Vol
69,816
52-wk High
$3.83
52-wk Low
$0.43

Chart for

About

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer. The Company's product pipeline includes Therapeutic (MVT-5873),... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $16.47
Shares Outstanding(Mil.): 20.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock

* MABVAX THERAPEUTICS HOLDINGS INC FILES FOR RESALE OF 16.6 MILLION SHARES OF CO'S COMMON STOCK BY CERTAIN OF CO'S STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2of4wAj) Further company coverage:

Dec 15 2017

BRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug

* MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

Dec 13 2017

BRIEF-Mabvax to present three posters at AACR-NCI-EORTC Int'l conference

* Mabvax therapeutics to present three posters at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-MabVax Therapeutics files for resale of 9.7 mln shares‍​

* MabVax Therapeutics Holdings Inc - files for resale of 9.7 million shares of common stock of co by certain stockholders ‍​ Source text: (http://bit.ly/2gBSIB6) Further company coverage:

Oct 25 2017

BRIEF-MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​

* MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​ Source text: [http://bit.ly/2x8TRa4] Further company coverage:

Oct 19 2017

BRIEF-MabVax Therapeutics Holdings provides corporate overview and business outlook

* MabVax Therapeutics Holdings Inc provides corporate overview and business outlook

Oct 17 2017

BRIEF-Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075

* Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers

Oct 11 2017

BRIEF-MabVax stockholders approve remaining proposal at stockholders meeting

* MabVax Therapeutics Holdings - ‍resolution approved to implement, if necessary a reverse stock split of company's issued and outstanding common stock​

Oct 06 2017

BRIEF-MabVax Therapeutics announces $1.25 mln registered direct offering

* MabVax Therapeutics Holdings announces $1.25 million registered direct offering

Sep 22 2017

BRIEF-John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings Inc

* John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings Inc as of September 11, 2017- SEC filing‍​ Source text: (http://bit.ly/2fwmYNQ) Further company coverage:

Sep 19 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.80 -0.05
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.55 -0.22
Eli Lilly and Co (LLY.N) $86.54 +0.04
Abbott Laboratories (ABT.N) $55.50 +0.77
Amgen, Inc. (AMGN.OQ) $177.04 +2.12

Earnings vs. Estimates